关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 一、涉嫌财报虚假记载 12月22日晚，长药控股发布《关于立案调查进展暨风险提示公告》称，公司存在重大违法强制退市风 险、不符合重整条件的风险及财务类强制退市风险。 11月7日，*ST长药（维权）披露公告称因涉财报虚假记载，根据相关法律法规证监会对其立案调查。 这一立案调查意味着*ST长药可能涉嫌财务造假，正式调查结束后，如果违法行为被确认，公司将面临 严重后果。 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 上海沪紫律师事务所刘鹏律师提示投资者索赔唯有主动通过法律途径维权，才能弥补部分损失。（刘鹏 律师专栏） （2）于2025年11月7日（含当日）之前买入，并在2025年11月8日之后卖出或仍持有而亏。 二、两类投资者可维权 *ST长药目前面临多重退市风险，而证监会的立案调查只是其中之一。目前债务缠身、财务状况恶化以 及公司治理和内部控制方面存在严重缺陷。 值得注意的是此前长药控股因资金占用引发的投资者索赔案件此前已获终审胜诉，且诉讼时效还未 ...

对此，上海百悦律师事务所合伙人律师牛彬向雷达财经表示，根据证券法及相关规定，上市公司不当行为给投资者造成损失的， 受损投资者可依法索赔。凡是在上市后到2025年12月19日之间买入，并且在2025年12月19日收盘时持有卓然股份股票的受损投资 者，可通过公号"雷助吧"（雷助码：77）报名，免费参与索赔。获赔前无任何费用。 雷达财经注意到，11月7日，卓然股份发布《2025年11月7日投资者关系活动记录表》。 2025年11月7日，卓然股份在上海证券交易所上证路演中心召开2025年第三季度业绩说明会，对投资者提问进行了解答。上市公司 接待人员是董事长张锦红，董事、总经理张军，董事会秘书张笑毓，财务总监吴玉同，独立董事郑凯。 雷达财经雷助吧出品 文|简白 编|深海 请问公司未来的分红计划和派息政策？对此，卓然股份回复称，公司始终高度重视股东回报，在保持经营稳健发展的基础上，坚 持推行稳定的分红政策。未来，公司将在充分考虑行业发展趋势、企业日常经营发展需要、股东权益诉求、社会资金成本、外部 融资环境等综合因素的基础上，秉承着公司发展与股东利益并重的原则，平衡股东的合理投资回报与公司长远发展，建立持续、 稳定、科学的 ...

Core Viewpoint - Long Pharmaceutical Holdings (长药控股) is facing legal actions due to allegations of false financial reporting and significant financial irregularities, with ongoing investor compensation claims being processed through the courts [1][3]. Group 1: Legal Proceedings - The law firm Shanghai Jucheng has submitted multiple claims to the Wuhan Intermediate People's Court on behalf of investors against Long Pharmaceutical Holdings, with previous successful cases serving as a precedent [1][3]. - The firm continues to accept claims from other investors who have suffered losses related to the company's stock [3]. Group 2: Financial Irregularities - Long Pharmaceutical Holdings announced on April 30, 2024, that it is under scrutiny for fund misappropriation and illegal guarantees, with an audit report highlighting significant uncertainties regarding its ongoing operations [4]. - The company reported a fund misappropriation amounting to 179,662,019.54 yuan, which represents 92.08% of its most recent audited net assets [4]. Group 3: Investor Compensation - Investors who purchased Long Pharmaceutical Holdings stock between March 30, 2019, and April 30, 2024, and sold or held their shares after April 30, 2024, are eligible to file for compensation based on previous successful judgments [5].

Core Viewpoint - The article discusses the significant legal developments regarding investor claims against Puli Pharmaceutical (300630) due to false statements made by the company, leading to a court ruling in favor of investors [1][3]. Financial Misstatements - Puli Pharmaceutical falsely reported sales revenue and profits by fabricating sales of finished and raw pharmaceutical products from 2021 to 2022. In 2021, the company overstated revenue by 436,606,838.34 yuan, which accounted for 28.94% of the reported revenue, and overstated profits by 308,018,435.49 yuan, representing 65.88% of the total reported profit [4][5]. - In 2022, the company overstated revenue by 456,639,341.72 yuan, which was 25.28% of the reported revenue, and overstated profits by 387,417,257.52 yuan, making up 88.27% of the total reported profit [4][5]. Additional Revenue Miscalculations - The company also miscalculated revenue from non-controlling trade activities, leading to an additional overstatement of 77,997,346.38 yuan in 2021 (5.17% of reported revenue) and 59,259,735.84 yuan in 2022 (3.28% of reported revenue) [2][6]. Legal Proceedings - The law firm Shanghai Jiucheng, led by attorney Xu Feng, is actively pursuing further claims and has already achieved a favorable ruling for investors in a recent case. Investors who purchased Puli Pharmaceutical shares between April 26, 2022, and April 17, 2024, are eligible to file claims [3][6].

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 2025年12月20日，贵州百灵企业集团制药股份有限公司（以下简称"贵州百灵"或"公司"）发布公告称， 公司及相关责任人收到贵州证监局下发的《行政处罚事先告知书》（黔处罚字[2025]1号-11号）。据处 罚内容，其因2019-2021年虚增利润及2023年虚减利润致四年年报虚假记载，公司被警告并罚款1000万 元，11名相关责任人合计罚款1560万元，公司股票被实施其他风险警示，不触及重大违法强制退市。上 海市信本律师事务所赵敬国律师（执业证号：13101200410820485）提示，（1）于2024年1月31日-2024 年4月29日期间买入且有持仓，无论在2024年4月30日及之后是否卖出；（2）于2020年4月30日-2024年4 月29日期间买入且有持仓，无论在2024年4月30日及之后是否卖出的受损投资者，或可通过"新浪股民维 权平台 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 上海久诚律师事务所股票索赔律师许峰提示，卓然股份（维权）（688121）涉嫌虚假陈述引发的投资者 索赔案已经启动。（许峰律师专栏） 2025年12月20日，卓然股份公告，卓然股份及实际控制人张锦红于2025年12月19日收到证监会出具的 《立案告知书》（证监立案字0032025031号、证监立案字0032025032号），因涉嫌信息披露违法违规等 事项，根据《证券法》《行政处罚法》等法律法规，证监会决定对公司及实际控制人张锦红立案。 许峰律师认为，在2025年12月20日之前买入卓然股份股票，并且在2025年12月20日后卖出或继续持有股 票的投资者，目前已可准备发起索赔。（卓然股份维权入口） 除了卓然股份投资者索赔案启动，12月19日，许峰律师代理的鹏都农牧（002505）投资者索赔提交法院 立案，律师团队还在继续推进后续案件的立案工作，还在继续 ...

Core Viewpoint - The article discusses ongoing legal actions against Nuotai Bio (688076) for false statements made in their financial reports, particularly regarding a technology transfer that inflated their reported revenue and profits in 2021 [1][2][3][4] Group 1: Legal Proceedings - The Shanghai Jucheng Law Firm, represented by lawyer Xu Feng, is handling the investor compensation case against Nuotai Bio, which has been officially filed in the Shanghai Financial Court [1][2] - The law firm is continuing to accept claims from other investors who have suffered losses due to the company's actions [1][2] Group 2: Financial Misconduct - Nuotai Bio's 2021 annual report contained false records, specifically a technology transfer transaction with Zhejiang Huabei, which was reported to generate revenue of 30 million yuan [3][4] - The transaction was deemed lacking commercial substance, as Zhejiang Huabei did not have the financial capability or operational capacity to utilize the technology, leading to an artificial inflation of revenue by 30 million yuan and a profit increase of 25.9516 million yuan, which accounted for 20.64% of the total profit reported for that period [3][4] Group 3: Investor Compensation Eligibility - Investors who purchased Nuotai Bio shares between April 28, 2022, and October 24, 2024, and sold or continued to hold them after October 24, 2024, are eligible to file for compensation [2][4]

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 2025年12月19日（周五）晚间，上海卓然工程技术股份有限公司（证券简称：卓然股份（维权），证券 代码：688121）发布《关于收到中国证券监督管理委员会立案告知书的公告》。公告显示，因涉嫌信息 披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监 会决定对公司立案。 在公告被证监会立案前，公司股价已连续调整。截至2025年12月19日收盘，股价报12.13元，近半年累 计下跌达25.6%。此次突发立案调查，使截至该日收盘持有的约六千名股东权益面临重大不确定性。鉴 于该公司为科创板上市企业，股票单日涨跌幅限制为20%，投资者应特别关注相关投资风险。 上海百悦律师事务所牛彬律师表示，卓然股份因涉嫌信披违规遭证监会立案，投资者或可依法索赔。初 步索赔范围（参考）： 于2025年12月19日（不含当日）之前买入卓然 ...

Core Viewpoint - The article discusses the legal progress regarding investor compensation claims against Ningke Biological (600165) due to false statements in financial reporting and failure to disclose significant events [1][5]. Group 1: Legal Developments - On December 18, 2025, significant progress was made in the investor compensation case against Ningke Biological, with some investors receiving compensation [1]. - The law firm representing the investors has filed additional claims in court [1]. - A court ruling has been received, confirming that investors have won their case [1]. Group 2: Regulatory Findings - On April 4, 2024, Ningke Biological announced that it received an administrative penalty decision from the Ningxia Regulatory Bureau of the CSRC, confirming violations [5]. - The company inflated its 2022 revenue by 76.5941 million yuan and profit by 77.222 million yuan, representing 11.25% and 46.59% of total revenue and profit, respectively [5]. - The company failed to timely disclose significant events, including major debts, frozen bank accounts, and the suspension of key subsidiary operations [2][3][4]. Group 3: Investor Compensation Eligibility - Investors who purchased Ningke Biological shares between November 22, 2022, and April 6, 2023, and sold or held shares after April 6, 2023, are eligible for compensation [7]. - Additionally, investors who bought shares between April 28, 2023, and October 31, 2024, and sold or held shares after October 31, 2024, can also initiate claims [7].

Core Viewpoint - The article discusses the ongoing legal actions against ChaoHua Technology (002288) for false statements made to investors, highlighting the firm's financial misconduct and the potential for investor compensation claims [1][3]. Group 1: Legal Proceedings - ChaoHua Technology's investor compensation case has been submitted multiple times to the Guangzhou Intermediate People's Court, with the legal team continuing to accept claims from affected investors [1][3]. - The law firm Shanghai Jucheng, led by lawyer Xu Feng, is actively pursuing these claims and is awaiting further court arrangements [1][3]. Group 2: Financial Misconduct - On March 4, 2025, ChaoHua Technology received an administrative penalty from the China Securities Regulatory Commission (CSRC) for financial misconduct, including inflating profits through fictitious copper trading and underreporting interest expenses [4]. - The 2020 annual report of ChaoHua Technology falsely inflated profits by CNY 5,033,833.35, which accounted for 30.22% of the total disclosed profit for that period [4]. - The company failed to disclose related party transactions and non-operating fund usage in its annual reports from 2018 to 2022 and the semi-annual report for 2023, indicating significant omissions [4][5]. Group 3: Investor Claims - Investors who purchased ChaoHua Technology shares between April 26, 2018, and February 29, 2024, and sold or continued to hold the shares after February 29, 2024, are eligible to file compensation claims [6].